Cancer Immunotherapy denotes a therapeutic intervention whereby a treatment aims to enable the body’s own immune system to fight and, eventually, clear the tumour. The field could be said is more than a 100 years old but has witnessed an enormous development in the last decades due to the development of sophisticated methods of immune intervention.
Many cases of patients cured of tumours previously regarded as untreatable have hit the headlines of popular news. However, once the spotlight goes off, the fact remains – immunotherapy, on average, seems to work only in a small fraction of patients and modern science does not still understand what differs among responders and non-responders, or how to predict one or another. It is a very active field of study and modern analytical tools are indispensable in enabling new discovery and pushing the boundaries of cancer patient care further.
Here I present examples how mass cytometry and single-cell RNA sequencing shape our understanding of tumour biology and open new avenues of research.
MEFST, petak, 21.09.2018., 12 sati, seminarska A430
